Data Integrity in the COVID-19 Era and Beyond
A Three-Part FDAnews/CenterWatch Virtual Conference Series



COVID-19 has spread across the globe and in an effort to quell the pandemic, the FDA responded with guidelines to expedite effective treatments and devices. They’ve set new regulations meant to hasten the development and approval of products that could prevent, diagnose or treat the virus.

These guidelines, along with the Coronavirus Treatment Acceleration Program, Operation Warp Speed and growing public pressure, have rapidly pushed forward the process of finding solutions to this massive health crisis.

But this swift pace hasn’t absolved manufacturers and researchers of their long-held data integrity responsibilities. While the processes may be moving at a quicker pace, these standards remain steadfast.

Concerned about how you can maintain the same essential data practices during these pressing times? Wondering how it’s possible to succeed in this fast-paced journey while sustaining the crucial standards of success you’ve set for your team?

This three-part FDAnews virtual conference has your answers.

  • Part I: The Impact of COVID-19: Complying with Data Integrity Guidelines in the Midst of a Pandemic
    Purchase as an Encore Presentation. Recorded on Thursday, Aug. 4, 2020

    1. Data Integrity in the Age of COVID-19
      1. The impacts of COVID-19 on operations and supply chain management
      2. Conducting clinical trials during the pandemic
      3. Data practices that may become the “new normal”

    2. FDA Regulations Around Data and COVID-19
      1. Guidance that most affects data integrity
      2. Regulations that may last beyond the pandemic
      3. Possible compliance issues in 2021

    3. Inspections and Audits
      1. General changes in inspection and audit practices
      2. Virtual inspections and audits, including challenges and best practices

  • Part II — Key Issues in Data Integrity: Today and Tomorrow
    Purchase as an Encore Presentation. Recorded on Wednesday, Sept. 23, 2020

    1. Managing Suppliers
      1. Keeping suppliers on track during a global pandemic
      2. Using technological developments to secure supply chains
      3. Dealing with problematic suppliers

    2. Measuring Testing and Validation Requirements
      1. Ensuring testing and validation meets good manufacturing practices requirements
      2. Taking advantage of technological updates
      3. Adapting to the “new normal” after the pandemic

    3. Dealing with Digital Transformation
      1. Making AI and blockchain work for you
      2. Complying with electronic submission requirements
      3. Preparing for post-pandemic digital obligations

  • Part III — The Real-World Costs of Data Integrity
    Wednesday, Oct. 28, 2020, 1:30 p.m. – 5:00 p.m. EDT

    1. Document and Data Creation, Maintenance and Archival: Best Practices
      1. Creating the data and documents you need to better obtain information for inspection compliance
      2. Maintaining and preserving documents through the latest technology
      3. Ensuring the deployment of industry best practices in inspection compliance

    2. Increasing Productivity through Effective Implementation of Data Integrity Concepts
      1. Determining which key data integrity concepts will best serve your organization
      2. Understanding how data integrity adherence can benefit both compliance and productivity
      3. Finding the lessons COVID-19 is teaching us about data integrity

    3.  Deploying a Solid Risk Management Strategy for Data Integrity
      1. Applying the ICH Q9 guidance when implementing an effective risk management strategy around data integrity
      2. Making sure your team has meaningful and effective risk management strategies based on the design, operation and monitoring of systems and controls, along with the risk to patients, process and product
      3. Finding the unique risk mitigation strategies your team can employ to ensure the integrity of electronic data systems
      4. Using audit trails as part of a risk management strategy
      5. Remediating data integrity problems through a risk management strategy

Don’t let data integrity compliance issues jeopardize the effectiveness, safety, and success of your medical products. This virtual conference will give you the tools you need to maintain this crucial element of your process, avoid new regulatory concerns, and manage COVID-19 data adjustments.

Join us by registering for this three-part series today.

Three-Part Series Pricing

Virtual Conference plus Recording & Transcript Bundle
Learn more


add to cart

Virtual Conference only
Learn more


add to cart

24/7 Encore plus Recording & Transcript Bundle
Learn more


add to cart

24/7 Encore Presentation
Learn more


add to cart

Virtual Conference Recording & Transcript Bundle
Learn more


add to cart
Click here to view
the speakers bios
Click here to view
the Part I agenda
Click here to view
the Part II agenda
Click here to view
the Part III agenda


Who Will Benefit

  • Pharmaceutical and device manufacturing teams
  • CROs and clinical trial sponsors
  • Data integrity consultants
  • Regulatory, quality, and compliance specialists
  • Clinical trial developers
  • Clinical study data experts
  • Vice presidents of strategic planning
  • Medical product attorneys
  • Drug and device consultants

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 | Fax 703.538.7676 | Toll free 888.838.5578 | Email

© 2020 FDAnews